Brown, S; Hinsley, S; Ballesteros, M; Bourne, S; McGarry, P; Sherratt, D; Flanagan, L; ... Myeloma UK Clinical Trials Network, .; + view all Brown, S; Hinsley, S; Ballesteros, M; Bourne, S; McGarry, P; Sherratt, D; Flanagan, L; Gregory, W; Cavenagh, J; Owen, R; Williams, C; Kaiser, M; Low, E; Yong, K; Myeloma UK Clinical Trials Network, .; - view fewer (2016) The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. BMC Hematology , 16 , Article 14. 10.1186/s12878-016-0053-9.